Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy

Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy

Conditions: CKD; Diabetic Kidney Disease; Type 2 Diabetes Mellitus in Obese; Obesity; Severe Obesity
Interventions: Drug: Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution; Drug: Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution
Sponsors: Geisinger Clinic
Terminated

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

February 10, 2024Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments